Category Fat Loss & Metabolism
Description Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that represents a novel approach to metabolic regulation. It functions by activating both incretin receptors simultaneously, leading to enhanced insulin secretion, reduced glucagon levels, delayed gastric emptying, and decreased appetite. This dual mechanism provides comprehensive metabolic effects including improved glycemic control, significant weight reduction, and favorable changes in body composition. Tirzepatide has been studied for its potential in treating type 2 diabetes and obesity, showing superior efficacy compared to single-receptor agonists. Research applications include investigating incretin biology, metabolic pathways, tissue repair mechanisms, and the relationship between glucose metabolism and weight management.



